<DOC>
	<DOC>NCT01635777</DOC>
	<brief_summary>Miltefosine efficacy will be &gt;85%</brief_summary>
	<brief_title>Safety and Efficacy of Oral Miltefosine in Patients With Post Kala Azar Dermal Leishmaniasis (PKDL)</brief_title>
	<detailed_description />
	<mesh_term>Miltefosine</mesh_term>
	<criteria>12 years or older nodules and papules consistent with post kalaazar dermal leishmaniasis parasitological confirmation of Leishmania infection platelet count &lt;100x 109/l, leukocyte count &lt;2.5 x 109/l , hemoglobin &lt; 8.0 g/100 ml , liver function tests &gt;3 times upper limit of normal range, bilirubin &gt;2 times upper limit of normal range, serum creatinine or blood urea nitrogen &gt;1.5 times upper limit of normal range); any noncompensated or uncontrolled condition, lactation, pregnancy, or likelihood of inadequate contraception in females of childbearing potential for the treatment period plus 2 months thereafter; treatment with any antileishmanial drug within the previous 12 weeks.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>PKDL</keyword>
	<keyword>miltefosine</keyword>
</DOC>